Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B–Cell lymphomas. Although the BTK-targeting agent ibrutinib has shown promising clinical responses, the presence of primary...

Full description

Bibliographic Details
Main Authors: Bhawana George, Sayan Mullick Chowdhury, Amber Hart, Anuvrat Sircar, Satish Kumar Singh, Uttam Kumar Nath, Mukesh Mamgain, Naveen Kumar Singhal, Lalit Sehgal, Neeraj Jain
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
ibrutinib
acquired resistance
genetic alterations
tumor microenvironment
BTK-PROTAC
CAR T-cells
Online Access:https://www.mdpi.com/2072-6694/12/5/1328

Internet

https://www.mdpi.com/2072-6694/12/5/1328

Similar Items